Product Information
PHENTERMINE-TOPIRAMATE ER 11.25-69 MG CAPSULE is a generic product labeled by Teva Pharmaceuticals USA Inc., priced at $3.0907 per EA under NDC 00480229956. Its NADAC has been published 55 times since Sep 17, 2025.
FDA first approved this application on Jun 25, 2024. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
11.25; 69 mg/1; mg/1
Manufacturer
Teva Pharmaceuticals USA Inc.NDC
00480229956
Classification
Generic
Dosage Form
CAPSULE, EXTENDED RELEASE
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
PHENTERMINE HYDROCHLORIDE; TOPIRAMATEApproval Type
Generic (ANDA)
FDA Application
ANDA204982FDA Approved
6/25/2024
TE Code
AB
On Market Since
5/7/2025
Pharmacological Classes
Price Statistics
The NADAC for PHENTERMINE-TOPIRAMATE ER 11.25-69 MG CAPSULE has been published 55 times since Sep 17, 2025, and over the history we have for it it has declined 29.9%. The table below summarizes its recorded NADAC range and movement.
| Current price | $3.0907 per EA |
|---|---|
| All-time high | $4.4066 (Oct 15, 2025) |
| All-time low | $3.0277 (Jun 17, 2026) |
| 52-week high | $4.4066 |
| 52-week low | $3.0277 |
| Median price | $3.2092 |
| Average price | $3.5844 |
| Largest weekly change | -13.4% (Feb 18, 2026) |
| Weeks tracked | 55 |
| Tracking since | Sep 17, 2025 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the Phentermine and topiramate market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Teva Pharmaceuticals USA Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Phentermine and topiramate market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Sympathomimetic Amine Anorectic class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of PHENTERMINE-TOPIRAMATE ER 11.25-69 MG CAPSULE?
The current National Average Drug Acquisition Cost (NADAC) for PHENTERMINE-TOPIRAMATE ER 11.25-69 MG CAPSULE, manufactured by Teva Pharmaceuticals USA Inc., is $3.0907 per EA (NDC 00480229956), effective Sep 30, 2026.
How has the price of PHENTERMINE-TOPIRAMATE ER 11.25-69 MG CAPSULE changed over time?
Over the history we have for it, the NADAC for PHENTERMINE-TOPIRAMATE ER 11.25-69 MG CAPSULE has declined 29.9%. It has been tracked across 55 weekly CMS publications since Sep 17, 2025.
What are the highest and lowest recorded NADAC prices for PHENTERMINE-TOPIRAMATE ER 11.25-69 MG CAPSULE?
Since Sep 17, 2025, the NADAC for PHENTERMINE-TOPIRAMATE ER 11.25-69 MG CAPSULE has ranged from a low of $3.0277 (Jun 17, 2026) to a high of $4.4066 (Oct 15, 2025), with a median of $3.2092 per EA.
Are there cheaper alternatives to PHENTERMINE-TOPIRAMATE ER 11.25-69 MG CAPSULE?
No other NADAC-published product currently shares the active ingredient and strength of PHENTERMINE-TOPIRAMATE ER 11.25-69 MG CAPSULE in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures PHENTERMINE-TOPIRAMATE ER 11.25-69 MG CAPSULE?
PHENTERMINE-TOPIRAMATE ER 11.25-69 MG CAPSULE (NDC 00480229956) is labeled by Teva Pharmaceuticals USA Inc., and CMS classifies it as a generic product.